SCHEMBL24508311

SCHEMBL24508311

NC(O)c1cccc(C(F)(F)F)n1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 1/20 0.54
P2RX7 Q99572 1/20 0.45
PNMT P11086 1/20 0.39
IDH1 O75874 5/20 0.37
NOTUM Q6P988 1/20 0.37
PGK1 P00558 1/20 0.36
PGK2 P07205 1/20 0.36
IDH2 P48735 1/20 0.36
TAS2R14 Q9NYV8 1/20 0.36
IRAK4 Q9NWZ3 2/20 0.34
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
AHR P35869 1/20 0.34
SCN9A Q15858 1/20 0.34
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA3 P34903 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20402885 0.84 ADRB1 (0.49) ADRB1P2RX7IDH1NOTUMIDH2
SCHEMBL19540540 0.84 ADRB1 (0.57) ADRB1P2RX7PNMTIDH1NOTUM
SCHEMBL27186114 0.81 ADRB1 (0.50) ADRB1P2RX7IDH1IDH2IRAK4
SCHEMBL13184023 0.81 ADRB1 (0.58) ADRB1P2RX7IDH1NOTUMIDH2
SCHEMBL27186121 0.81 ADRB1 (0.50) ADRB1P2RX7IDH1IDH2IRAK4
SCHEMBL8124122 0.80 ADRB1 (0.61) ADRB1P2RX7PNMTIDH1NOTUM
SCHEMBL18793684 0.80 ADRB1 (0.50) ADRB1P2RX7PNMTIDH1NOTUM
SCHEMBL28151259 0.78 ADRB1 (0.50) ADRB1P2RX7IDH1NOTUMPGK1
SCHEMBL30676298 0.78 ADRB1 (0.51) ADRB1P2RX7PNMTIDH1NOTUM
SCHEMBL17574510 0.77 ADRB1 (0.50) ADRB1P2RX7IDH1NOTUMIDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11779578-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-10-10 US disclosed
WO-2022125790-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11779578-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 ADRB1 4186/4885P2RX7 1103/4885PNMT 4198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.